NCT04314817View on ClinicalTrials.gov

Adverse Events Related to Treatments Used Against Coronavirus Disease 2019

CompletedOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

March 17, 2020

Primary Completion Date

January 1, 2023

Study Completion Date

January 1, 2023

Conditions
CoronavirusIatrogenic DiseaseAcute Kidney InjuryARDS, Human
Interventions
DRUG

Any drug used to treat Covid-19

lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.

Trial Locations (1)

Unknown

AP-HP Assistance Publique Hopitaux de Paris, Paris

All Listed Sponsors
collaborator

CMC Ambroise Paré

OTHER

lead

Groupe Hospitalier Pitie-Salpetriere

OTHER

NCT04314817 - Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 | Biotech Hunter | Biotech Hunter